Crenolanib - AROG Pharmaceuticals

Drug Profile

Crenolanib - AROG Pharmaceuticals

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals; University of Ulm
  • Class Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Acute myeloid leukaemia; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma; Non-small cell lung cancer
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Systemic mastocytosis
  • Research Soft tissue sarcoma
  • No development reported Cancer; Glioma

Most Recent Events

  • 14 Jun 2018 Interim adverse events data from a phase II trial in Acute myeloid leukaemia 23rd Congress of the European Haematology Association (EHA-2018)
  • 05 Jun 2018 Phase-III clinical trials in Acute myeloid leukaemia (Adjunctive treatment, Refractory metastatic disease, Second-line therapy or greater) in Hungary, USA (PO) (NCT03250338)
  • 01 Feb 2018 Arog Pharmaceuticals completes a phase I/II trial for Acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA (NCT02626338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top